Member Info for AquaeSulis01

https://www.ii.co.uk/analysis-commentary/ceres-power-qa-update-popular-green-energy-firm-ii520589

Joy the Market has compared the half year report where "The first six months of this year has seen strong revenue growth with a 400% increase in group income and individual divisions reporting a 1,309% (SlimBiome®) and 477% (LPLDL®) increase in revenues. This was achieved against a 15.5% reduction in other administration costs and a 50% reduction in the loss compared to the same period last year" with a drop for the year as a whole to 104%.

Covid quite rightly has been flagged up as a reason for the second half pullback but until the figures for 2021 are produced this September which show that the second half fall was a once off, or some big news is announced, the market is being cautious

Hi skid, know what you mean. I would suggest your holding prior to today remains your LTH for Opti which has an awful lot of upside and little downside risk whilst you set yourself maybe a minimum shorter term 10% profit target for today's trade. Worst case scenario is no significant news before the half year announcement in Sept which should reflect the revenue impact post covid delays of the larger deals and margin improvements, good luck us all

Nothing to stop you being both a trader and LTH!

Whilst the no share price growth is true, another way is to view the range the share price has operated within over the past 12 mths hitting a high of 69p which is a 50% jump on today's price and not too shabby for the traders out there I would suggest

Laird, they are available from the Opti online store, hover over the "Shop" drop down and they appear as an option

https://optibiotix.online

Well confirmation bythe auditors that the Skin investment belongs in the profit and loss column but the excitng part of this report from me is this section:

"Stephen O'Hara, CEO of OptiBiotix, commented: "This has been a pivotal year for OptiBiotix with doubling sales and a large reduction in costs enabling our Probiotic and Functional Fibre divisions to achieve profitability. This is a substantive change from divisional losses of £467,704 for ProBiotix and £451,572 for the functional fibre division reported in 2019. This was particularly pleasing given the impact of the COVID-19 pandemic and global recession in key markets, with weight management markets experiencing a 9% decline in growth. The Company has also benefited from an increase in the value of OptiBiotix's holding in SBTX which is making strong progress on its path to commercialising products.



"The Company is now in a position of having established the scientific, clinical and commercial viability of its first-generation products (LPLDL® and SlimBiome®) with a network of internationally recognised partners who are extending product ranges and territories providing a solid basis for future growth. We are also pleased to report commercial progress with our pipeline of exciting second-generation products with the industrial scale up of a range of our innovative SweetBiotix products and a number of large corporates signing Material Transfer Agreements as they develop applications containing SweetBiotix.



"We have continued to make progress since the beginning of the current financial year with strong sales growth and larger orders as existing partners extend their product range and territories. Our focus remains on growing sales of first generation products with larger partners in key strategic markets like India, the USA, and China, and commercialising our pipeline of second generation products in the year ahead.



"With interest in the microbiome increasing, growing sales, increasing margins, reducing costs, and an exciting pipeline of industry disruptive second-generation products, the Company is in a strong position for future growth in this exciting area of healthcare."

Good to share opinions, personally I enjoy visual and audio presentations alongside RNS's or Reach RNS's but certainly room for both

loads "1. Why does SOH persist in conducting the MAJORITY of Opti's investor relations via Elrico? This is a listed company for God's sake and the proper channel should be via RNSs, not some private individual (no offence intended to Elrico)"

Can you please justify that statement; how many interviews have there been with elric as opposed to RNS's released and proactive interviews etc?

What you get from an Elric or Tom W interview that you don't get from a company paid for publication or proactive interview is the sort of question asked and answered that you or I as shareholders would like to see posed; without these sort of interviews which Tom W charges a once off 99p for and elric releases for free a short time after, you would miss out altogether. There is nothing said in these interviews that warrant a RNS and as 1gandhi has said valuations provided by the CEO should be treated with a pinch of salt (or cholbiome if you want to keep your blood pressure down).

On the comms front where I do have an issue is the lack of marketing for some really great products already available in store and elsewhere. The fruit boosts which as a shareholder I stumbled across by accident in the online store are a revelation. i have let a number f friends and neighbours try the mango and strawberry fruit boosts in water and they love them, but when the packaging costs as much or more than the product, joe public just isn't going to take a chance on them even if they did stumble across them. Why SOH doesn't take a hit on margins and go for volume sales in supermarkets on this product that could potentially mop the floor with current bottled juices is beyond me.

1ghandi, suggest you listen to elrico's podcast with the CEO where the CEO himself estimates the value of Slimbiome and LPLDL to be worth circa £100M each, and Sweetbiotix following a commercial launch £100M - £500M

https://soundcloud.app.goo.gl/LtcUH

What does appear to be happening is the ramp up in deals with the partnerships. Besides the H&B Slim expert range, where the porridge and meal replacements are listed near the top of the most popular selling weight management products (I personally love the syrup flavoured porridge and bought the last two boxes on display in my local Bath store), things seem to be finally moving in the India market where the ZeoSlim range containing Slimbiome is being heavily marketed by the partner and is now also sold through Amazon in India.

https://www.amazon.in/ZEON-Clinically-Replacement-Supplement-Alternative/dp/B08LVSVFT7

No it's not correct. Skin Mc is £101.12M as at yesterday and Opti own 23.1% of the company

CPI figures are out at 13;30 with expectations as follows

Thursday will see the release of the week's key data point, a report on US consumer prices in May.
Consensus is for headline CPI to have accelerated from a 4.2% clip in April to 4.6% for last month.

Increases in core CPI are also expected to have quickened alongside, from 3.0% to 3.4%.

Fair comment Bubs, the daily volume on Opti has been pitifully low for months. This needs one of the six "final detail stage" major RNS's that SOH has spoken of with elric to move it. Besides finally seeing a sweetbiotix commercial launch, the 900k pharma product launch sounds huge and must include India with circa 800,000 pharmacies. By contrast in the EU, there were almost 97,000 pharmacies compared with about 64,000 pharmacies in the U.S. The total number of pharmacies in each of the five major EU countries range from 14,000 pharmacies in the United Kingdom to 22,455 in France.

Or a picture with a securicor van outside ready to take away the core samples :)

Simon, I am not sure that I suggested that it was unusual, in fact I used it to illustrate to Boyo that there was likely nothing untoward in the Ceres sp action

Just missing a bit of basic research Corby; try watching the latest media presentation on the Company's website for strters

https://www.powermetalresources.com

https://www.telegraph.co.uk/business/2021/06/08/markets-live-latest-coronavirus-news-pound-euro-ftse-100/
Augurs well for tackling cyber attacks
Bitcoin ransom recovered
Bitcoin has fallen more than 2pc and tumbled almost 6pc at one point in Asian trading. The cause of the latest slide is unclear but could be related to the recovery of a high-profile Bitcoin ransom in the US.

The US Justice Department on Monday said it had recovered some $2.3m in cryptocurrency ransom paid by Colonial Pipeline, cracking down on hackers who launched the most disruptive US cyberattack on record.

Deputy Attorney General Lisa Monaco said investigators had seized 63.7 Bitcoins paid by Colonial after last month's hack of its systems that led to massive shortages at US East Coast gas stations.

The fact that investigators “could trace the untraceable and seize it might be undermining the libertarian, free-of-government-control case,” Jeffrey Halley, a senior market analyst at Oanda, told Bloomberg. The implications of that may have provoked the selling, he said

Ballard Power turned round an early deficit that ran during LSE opening hours with an after hours finish over 6% up and I have previously noticed Ceres and ITM paralleling with Ballards so could be in for a good day tomorrow

elric, first of all ty for placing this podcast in the public domain and for your research effort.

At 52/53 minutes in, SOH mentions half a dozen big announcements in the final detail stages of conclusion in response to your Sweetbiotix for H2 question. For one of those deals SOH mentioned opti products going into 900,000 pharmacies in a phased manner, now when Stuart Ashman mentioned a supply restricted 25,000 subscription target for axisbiotix on launch you were all over it working out the revenue implications, and yet you let SOH's claim go completely unchallenged without any revenue projections attached to it despite the fact that you would need the combined pharmacies from India and China to get anywhere near the 900,000 target and just say one box of Cholbiome sold per annum at £23 would generate over £18M in revenue. Why didn't you follow up on this?